摘要
目的:观察人免疫球蛋白联合阿昔洛韦治疗病毒性脑炎(VE)患者的效果。方法:回顾性分析2021—2023年该院收治的78例VE患者的临床资料,按照治疗方法不同将其分为对照组和研究组各39例。两组均予以基础治疗,在此基础上,对照组予以阿昔洛韦治疗,研究组在对照组基础上联合人免疫球蛋白治疗,两组均持续治疗10 d。比较两组临床疗效,症状消失时间,治疗前后脑脊液炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、降钙素原(PCT)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+))水平,以及不良反应发生率。结果:研究组治疗总有效率为94.87%(37/39),高于对照组的76.92%(30/39),差异有统计学意义(P<0.05);研究组头痛、呕吐、抽搐、精神行为异常等症状消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,研究组脑脊液IL-6、TNF-α、PCT水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组CD3^(+)、CD4^(+)水平高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:人免疫球蛋白联合阿昔洛韦治疗VE患者可提高治疗总有效率,缩短症状消失时间,降低脑脊液炎性因子水平,改善T细胞亚群指标水平,效果优于单纯阿昔洛韦治疗。
Objective:To observe effects of human immunoglobulin combined with Acyclovir in treatment of patients with viral encephalitis(VE).Methods:The clinical data of 78 patients with VE admitted to this hospital from 2021 to 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and study group,39 cases in each group.Both groups were given basic treatment.On this basis,the control group was treated with Acyclovir,while the study group was treated with human immunoglobulin on the basis of that of the control group.Both groups were treated for 10 d.The clinical efficacy,the symptom disappearance time,the cerebrospinal fluid inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),procalcitonin(PCT)]levels,the T cell subsets indexes(CD3^(+),CD4^(+),CD8^(+))levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.87%(37/39),which was higher than 76.92%(30/39)of the control group,and the difference was statistically significant(P<0.05).The disappearance time of headache,vomiting,convulsions,mental and behavioral abnormalities in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of IL-6,TNF-αand PCT in cerebrospinal fluid of the study group were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+)and CD4^(+)in the study group were higher than those in the control group,the level of CD8^(+)was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Human immunoglobulin combined with Acyclovir in the treatment of the VE patients can improve the total effective rate of treatment,shorten the symptom disappearance time,reduce the levels of inflammatory factors in cerebrospinal fluid,and improve the levels of T cell subsets.Moreover,it is superior to simple Acyclovir treatment.
作者
朱明振
刘素梅
牛智领
张圣楠
ZHU Mingzhen;LIU Sumei;NIU Zhiling;ZHANG Shengnan(Department of Neurology of Puyang People’s Hospital,Puyang 457000 Henan,China)
出处
《中国民康医学》
2025年第1期21-23,共3页
Medical Journal of Chinese People’s Health
